Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Thomas B. Smith Sells 9,593 Shares

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Thomas B. Smith sold 9,593 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the sale, the executive vice president now directly owns 53,816 shares in the company, valued at approximately $1,970,741.92. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Collegium Pharmaceutical Stock Up 0.7 %

Shares of NASDAQ:COLL opened at $37.38 on Wednesday. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. The company has a market capitalization of $1.20 billion, a P/E ratio of 15.58 and a beta of 0.94. Collegium Pharmaceutical, Inc. has a 52-week low of $20.95 and a 52-week high of $40.95. The stock’s fifty day simple moving average is $35.65 and its 200-day simple moving average is $35.41.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The company had revenue of $145.28 million for the quarter, compared to analyst estimates of $143.94 million. During the same period in the prior year, the firm earned $1.13 EPS. The firm’s quarterly revenue was up 7.2% on a year-over-year basis. As a group, equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several institutional investors and hedge funds have recently modified their holdings of COLL. Pacer Advisors Inc. grew its stake in Collegium Pharmaceutical by 31.8% in the 2nd quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after acquiring an additional 821,541 shares during the period. Rubric Capital Management LP boosted its holdings in shares of Collegium Pharmaceutical by 27.2% during the second quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock worth $75,139,000 after purchasing an additional 499,473 shares during the last quarter. Vanguard Group Inc. increased its stake in Collegium Pharmaceutical by 0.8% in the first quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock valued at $90,479,000 after purchasing an additional 17,942 shares during the last quarter. Principal Financial Group Inc. increased its stake in Collegium Pharmaceutical by 8.2% in the second quarter. Principal Financial Group Inc. now owns 1,680,860 shares of the specialty pharmaceutical company’s stock valued at $54,124,000 after purchasing an additional 128,003 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in Collegium Pharmaceutical by 8.0% during the second quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock worth $49,314,000 after buying an additional 113,300 shares during the period.

Wall Street Analysts Forecast Growth

COLL has been the subject of several research reports. HC Wainwright lifted their price objective on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, September 5th. Truist Financial lifted their price target on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Jefferies Financial Group upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $41.00 to $44.00 in a research report on Friday, June 7th. Piper Sandler restated a “neutral” rating and set a $37.00 target price (down from $39.00) on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Finally, StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 31st. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $42.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.